Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Biofrontera Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

WOBURN, MASS., OCT. 23, 2025 (GLOBE NEWSWIRE) -- BIOFRONTERA INC. (NASDAQ: BFRI) (BIOFRONTERA OR THE COMPANY), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT AND COMMERCIALIZATION OF PHOTODYNAMIC THERAPY (PDT), TODAY ANNOUNCED THE CLOSING OF ITS RESTRUCTURING AND ASSET PURCHASE AGREEMENT WITH ITS FORMER PARENT COMPANY, BIOFRONTERA AG. UNDER THE TRANSACTION, BIOFRONTERA INC. HAS ACQUIRED ALL U.S. ASSETS AND RIGHTS RELATED TO AMELUZ AND RHODOLED, INCLUDING THE NEW DRUG APPLICATION (NDA), INVESTIGATIONAL NEW DRUG APPLICATION (IND), MANUFACTURING RIGHTS AND CONTRACTS, ALL INTELLECTUAL PROPERTY, AND RELATED PERSONNEL.

BIOFRONTERA INC. CLOSES PURCHASE OF ALL AMELUZ AND RHODOLED US ASSETS FROM BIOFRONTERA AG

WOBURN, MA, SEPT. 26, 2025 (GLOBE NEWSWIRE) -- BIOFRONTERA INC., (NASDAQ:BFRI) ("BIOFRONTERA" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE COMMERCIALIZATION OF DERMATOLOGICAL PRODUCTS, TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN A WEBCAST PRESENTATION AND HOST ONE-ON-ONE MEETINGS WITH INVESTORS AT THE LYTHAM PARTNERS FALL 2025 INVESTOR CONFERENCE, TAKING PLACE VIRTUALLY ON TUESDAY, SEPTEMBER 30, 2025.

BIOFRONTERA INC. TO PARTICIPATE IN THE LYTHAM PARTNERS FALL 2025 INVESTOR CONFERENCE ON SEPTEMBER 30, 2025

WOBURN, MASS., SEPT. 23, 2025 (GLOBE NEWSWIRE) -- BIOFRONTERA INC. (NASDAQ: BFRI) (BIOFRONTERA OR THE COMPANY), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT AND COMMERCIALIZATION OF PHOTODYNAMIC THERAPY (PDT), HAS ENGAGED LYTHAM PARTNERS TO LEAD A STRATEGIC INVESTOR RELATIONS AND SHAREHOLDER COMMUNICATION PROGRAM.

BIOFRONTERA INC. ENGAGES LYTHAM PARTNERS TO LEAD STRATEGIC INVESTOR RELATIONS AND SHAREHOLDER COMMUNICATION PROGRAM

WOBURN, MASS., SEPT. 16, 2025 (GLOBE NEWSWIRE) -- BIOFRONTERA INC. (NASDAQ: BFRI) (BIOFRONTERA OR THE COMPANY), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT AND COMMERCIALIZATION OF PHOTODYNAMIC THERAPY (PDT), TODAY ANNOUNCED THAT THE FINAL PATIENT COMPLETED THE ACTIVE TREATMENT PHASE OF ITS PHASE 3 CLINICAL TRIAL EVALUATING AMELUZ (10% 5-AMINOLEVULINIC ACID HYDROCHLORIDE GEL) PDT FOR MILD TO MODERATE ACTINIC KERATOSES (AKS) ON THE EXTREMITIES, NECK AND TRUNK ON SEPTEMBER 3, 2025. ALL 172 ENROLLED PATIENTS HAVE NOW ENTERED THE 12-MONTH FOLLOW-UP PHASE, EXPECTED TO CONCLUDE IN Q2 2026.

BIOFRONTERA INC. ANNOUNCES LAST PATIENT OUT IN PHASE 3 STUDY OF AMELUZ (AMINOLEVULINIC ACID HCI) TOPICAL GEL, 10% PHOTODYNAMIC THERAPY (PDT) FOR THE TREATMENT OF ACTINIC KERATOSES (AK) ON THE EXTREMITIES, NECK AND TRUNK

WOBURN, MASS., AUG. 25, 2025 (GLOBE NEWSWIRE) -- BIOFRONTERA INC. (NASDAQ: BFRI) (BIOFRONTERA OR THE COMPANY), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT AND COMMERCIALIZATION OF PHOTODYNAMIC THERAPY (PDT), TODAY ANNOUNCED THAT THE FINAL PATIENT IN ITS PHASE 2B CLINICAL TRIAL EVALUATING AMELUZ (AMINOLEVULINIC ACID HYDROCHLORIDE) FOR THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS (AV) COMPLETED PARTICIPATION ON AUGUST 22, 2025.

BIOFRONTERA INC. ANNOUNCES LAST-PATIENT-OUT IN PHASE 2B STUDY OF AMELUZ (AMINOLEVULINIC ACID HCI) TOPICAL GEL, 10% FOR THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS

WOBURN, MA, AUG. 13, 2025 (GLOBE NEWSWIRE) -- BIOFRONTERA INC. (NASDAQ:BFRI) (THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT AND COMMERCIALIZATION OF PHOTODYNAMIC THERAPY IN DERMATOLOGY, TODAY REPORTED FINANCIAL RESULTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND PROVIDED A BUSINESS UPDATE.

BIOFRONTERA INC. REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

WOBURN, MA, AUG. 11, 2025 (GLOBE NEWSWIRE) -- BIOFRONTERA INC. (NASDAQ: BFRI) (THE COMPANY), A BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF PHOTODYNAMIC THERAPY (PDT), TODAY ANNOUNCED THE APPOINTMENT OF GEORGE JONES AS CHIEF COMMERCIAL OFFICER (CCO), STARTING AUGUST 25, 2025. IN THIS ROLE, MR. JONES WILL OVERSEE THE COMPANY'S COMMERCIAL FUNCTIONS, INCLUDING SALES, MARKETING, AND MARKET ACCESS. HE WILL REPORT DIRECTLY TO CEO DR. HERMANN LUEBBERT.

BIOFRONTERA INC. APPOINTS GEORGE JONES AS CHIEF COMMERCIAL OFFICER

WOBURN, MA, AUG. 04, 2025 (GLOBE NEWSWIRE) -- BIOFRONTERA INC., (NASDAQ:BFRI) ("BIOFRONTERA" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE COMMERCIALIZATION OF DERMATOLOGICAL PRODUCTS, ANNOUNCES IT WILL REPORT FINANCIAL RESULTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 ON WEDNESDAY, AUGUST 13, 2025. THE RESULTS WILL BE RELEASED AFTER THE MARKET CLOSE ON WEDNESDAY, AUGUST 13 AND THE COMPANY WILL HOST A CONFERENCE CALL ON THURSDAY, AUGUST 14 AT 10:00AM EASTERN TIME.

BIOFRONTERA INC. TO REPORT SECOND QUARTER FY 2025 FINANCIAL RESULTS ON AUGUST 13, 2025

BIOFRONTERA INC. HAS SIGNED AN AGREEMENT TO ACQUIRE ALL US ASSETS RELATED TO AMELUZ AND RHODOLED INCLUDING NEW DRUG APPLICATION (NDA) AND ASSOCIATED PATENTS FROM GERMANY-BASED BIOFRONTERA AG. UNDER THEIR NEW AGREEMENT, THE EFFECTIVE ROYALTY RATE PAID BY BIOFRONTERA INC. WILL BE REDUCED TO 12% (AND 15% ABOVE REVENUE OF $65 MILLION) OF NET SALES FROM 25% - 35% OF NET SALES.

BIOFRONTERA INC. ANNOUNCES MAJOR RESTRUCTURING OF RELATIONSHIP WITH BIOFRONTERA AG BACKED BY $11 MILLION INVESTMENT

WOBURN, MASS., JUNE 11, 2025 (GLOBE NEWSWIRE) -- BIOFRONTERA INC. (NASDAQ: BFRI), A BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF PHOTODYNAMIC THERAPY (PDT), CONFIRMS A DISCLOSURE BY THE MANAGEMENT BOARD OF BIOFRONTERA AG ON JUNE 10, 2025, ACCORDING TO WHICH THE TWO COMPANIES ARE IN NEGOTIATIONS REGARDING A POSSIBLE COMBINATION OF THE TWO COMPANIES OR AN ADJUSTMENT OF THE LICENSE AND SUPPLY AGREEMENT BETWEEN THEM. THE LATTER COULD RESULT IN THE TRANSFER OF CERTAIN RIGHTS AND OBLIGATIONS FROM BIOFRONTERA AG TO BIOFRONTERA INC. AND A REDUCTION IN THE TRANSFER PRICE FOR BIOFRONTERA INC.'S LICENSED PRODUCTS SOLD IN THE US.

Biofrontera Inc.

BFRI

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Biofrontera Inc.

BFRI.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

BFRI